Compare ZWS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZWS | CYTK |
|---|---|---|
| Founded | 1892 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.6B |
| IPO Year | 2008 | 2004 |
| Metric | ZWS | CYTK |
|---|---|---|
| Price | $47.26 | $63.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 18 |
| Target Price | $49.33 | ★ $87.56 |
| AVG Volume (30 Days) | 774.6K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,530,500,000.00 | $13,368,000.00 |
| Revenue This Year | $6.90 | $9.79 |
| Revenue Next Year | $5.13 | $302.66 |
| P/E Ratio | $41.12 | ★ N/A |
| Revenue Growth | ★ 19.40 | N/A |
| 52 Week Low | $27.74 | $29.31 |
| 52 Week High | $53.17 | $70.98 |
| Indicator | ZWS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 50.66 |
| Support Level | $45.14 | $59.25 |
| Resistance Level | $48.40 | $65.93 |
| Average True Range (ATR) | 1.25 | 2.54 |
| MACD | -0.57 | -0.34 |
| Stochastic Oscillator | 27.37 | 41.35 |
Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.